US Broker Ratings

Insmed Incorporated (INSM): An In-Depth Stock Analysis Reveals an 87% Potential Upside

Insmed Incorporated (NASDAQ: INSM), a prominent player in the biotechnology sector, is capturing investor attention with its robust pipeline of therapies targeting serious and rare diseases. With a market capitalization..

Natera, Inc. (NTRA) Stock Analysis: Impressive Revenue Growth Amidst a Challenging Valuation Landscape

Natera, Inc. (NTRA), a leader in the diagnostics and research industry, has been drawing significant attention from investors, with its market capitalization reaching an impressive $31.99 billion. The company, headquartered..

Genmab A/S (GMAB) Stock Analysis: A 39.83% Potential Upside in the Biotech Sector

For investors seeking opportunities in the biotechnology sector, Genmab A/S (NASDAQ: GMAB) presents a compelling proposition, with a potential upside of 39.83% based on current analyst ratings. This Danish company,..

Zimmer Biomet Holdings, Inc. (ZBH): Investor Outlook with a 19.88% Potential Upside

Zimmer Biomet Holdings, Inc. (NYSE: ZBH), a prominent player in the healthcare sector, specializes in the medical devices industry, offering a robust portfolio of orthopedic reconstructive products and cutting-edge digital..

Globus Medical, Inc. (GMED): Investor Outlook and Potential 34% Upside

Globus Medical, Inc. (NYSE: GMED), a leading player in the medical device sector, presents a compelling opportunity for investors, particularly with a significant potential upside of 34.34%. As a company..

Viatris Inc. (VTRS) Stock Analysis: Exploring an 11% Potential Upside Amid Mixed Metrics

As individual investors seek opportunities in the healthcare sector, Viatris Inc. (NASDAQ: VTRS) presents a compelling case with its substantial market presence and diverse pharmaceutical portfolio. With a market capitalization..

Revolution Medicines, Inc. (RVMD) Stock Analysis: A Biotech Powerhouse with Promising Potential and Analyst Confidence

Revolution Medicines, Inc. (NASDAQ: RVMD) is making significant strides in the biotechnology sector with its focus on developing targeted therapies for RAS-addicted cancers. With a market capitalization of $33.48 billion,..

Amgen Inc. (AMGN) Stock Analysis: Navigating a 4.59% Potential Upside Amid Strong Revenue Growth

Amgen Inc. (NASDAQ: AMGN), a titan in the healthcare sector with a market capitalization of $181.77 billion, continues to capture investor attention due to its robust portfolio and strategic collaborations...

ResMed Inc. (RMD) Stock Analysis: Navigating a 42% Potential Upside in the Healthcare Sector

ResMed Inc. (RMD), a prominent player in the healthcare sector, has garnered significant attention from investors due to its strong market positioning and innovative product offerings in the medical instruments..

Tempus AI, Inc. (TEM) Stock Analysis: Exploring a 33.15% Potential Upside Amidst Healthcare Innovation

In the rapidly evolving landscape of healthcare technology, Tempus AI, Inc. (NASDAQ: TEM) stands out as a pioneering force, offering innovative solutions in health information services. With a market capitalization..

Bio-Techne Corp (TECH) Stock Analysis: Exploring a Potential 18.84% Upside

Bio-Techne Corporation (NASDAQ: TECH), a prominent player in the biotechnology sector, offers an intriguing proposition for investors looking for growth opportunities in the healthcare industry. Headquartered in Minneapolis, Minnesota, Bio-Techne..

Incyte Corporation (INCY) Stock Analysis: Exploring a Strong 11.6% Potential Upside for Investors

Incyte Corporation (NASDAQ: INCY), a leading player in the biotechnology sector, presents a compelling opportunity for investors seeking growth in the healthcare industry. Headquartered in Wilmington, Delaware, Incyte has made..

ICON plc (ICLR) Stock Analysis: A Strategic Play in Healthcare with 8.54% Upside Potential

ICON plc (NASDAQ: ICLR), a leading player in the healthcare sector, specifically within the diagnostics and research industry, stands out with its robust infrastructure in clinical research and development services...

Agilent Technologies, Inc. (A) Stock Analysis: Strong Buy Ratings and 19% Potential Upside Drive Investor Interest

Agilent Technologies, Inc. (NYSE: A), a leader in the diagnostics and research industry, continues to capture the attention of investors with strong buy ratings and a promising growth outlook. With..

United Therapeutics Corporation (UTHR) Stock Analysis: Exploring a 19.47% Potential Upside

United Therapeutics Corporation (NASDAQ: UTHR) stands as a notable player in the healthcare sector, specifically within the niche of drug manufacturers focused on specialty and generic products. Headquartered in Silver..

argenx SE (ARGX) Stock Analysis: Envisioning a 23% Upside with Robust Revenue Growth

argenx SE (ARGX) is making waves in the biotechnology sector with its promising pipeline of autoimmune disease therapies. Based in Amsterdam, the Netherlands, this commercial-stage biopharma company has carved out..

Gilead Sciences, Inc. (GILD) Stock Analysis: Strong Buy Ratings and 17% Upside Potential

Gilead Sciences, Inc. (NASDAQ: GILD), a stalwart in the healthcare sector, continues to capture investor attention with its robust portfolio of innovative therapeutics targeting significant unmet medical needs. With a..

Qiagen N.V. (QGEN) Stock Analysis: Healthcare Innovator with Nearly 20% Upside Potential

Qiagen N.V. (NASDAQ: QGEN) stands as a key player in the healthcare industry, specifically within the diagnostics and research segment. Headquartered in Venlo, the Netherlands, Qiagen specializes in transforming biological..

Corcept Therapeutics (CORT) Stock Analysis: Exploring a 26.64% Potential Upside in the Biotechnology Sector

Corcept Therapeutics Incorporated (CORT), a prominent player in the biotechnology sector, is garnering attention from investors with its promising pipeline and potential upside of 26.64%, as indicated by recent analyst..

Doximity, Inc. (DOCS) Stock Analysis: Evaluating the 17.52% Upside Potential for Investors

Doximity, Inc. (DOCS) is making waves in the healthcare sector, specifically within the health information services industry. With a current market capitalization of $3.91 billion, Doximity has established itself as..

Search

Funds

US Broker Ratings

Search

Funds

US Broker Ratings

FTSE 100

Funds